ChemDmart
Chemxpert Database
  • About
    • About
    • Leadership
    • Advisory Board
  • Products
    • ChemProtel - Product Intelligence
    • CompFolio - One Company Profile
    • CompGroupe - Group Company Profile
    • ChemScape - Data Landscape
    • ChemDmart - E-Market Place
    • DataIntel - Data Analytics/Trends
    • DataFeed - Data News/Feed
    • CompShow- Company Showcase
  • Sources
  • Subscription
  • User Guide
  • Contact
  • Book Demo Log In
  1. Home
  2. All News
  3. Receptor Life Sciences Announces Fda Acceptance Of Ind Application For Rls103 Inhaled Dry Powder Cbd And Initiation Of Ind Opening Clinical Safety And Efficacy Study
News Feed
course image
  • 01 Apr 2022
  • Admin
  • News Article

Receptor Life Sciences Announces FDA Acceptance of IND Application for RLS103 (Inhaled Dry Powder CBD) and Initiation of IND-Opening Clinical Safety and Efficacy Study

Receptor Life Sciences (RLS), a pharmaceutical company developing innovative therapies to address central nervous system disorders, announced the U.S. Food and Drug Administration (FDA) accepted its Investigational New Drug (IND) application for RLS103. RLS103, a dry powder inhaled cannabidiol (CBD), is a first-in-class drug/device combination product for the acute treatment of social anxiety disorder. RLS103 uses a drug delivery technology comprising a proprietary CBD inhalation powder and a breath-powered device used in an FDA-approved product. RLS is initiating a proof-of-concept Phase 1b clinical safety and efficacy study in social anxiety disorder. The results will be used to facilitate the design of a larger, well-controlled, randomized Phase 2/3 safety and efficacy study intended for registration. The RLS103 inhalation powder contains synthetic CBD and FDKP, an FDA-approved inhalation excipient. In an initial proof-of-concept pharmacokinetic clinical study, RLS103 provided immediate CBD absorption with peak concentration less than 4 minutes after inhalation. Compared to oral CBD (Epidiolex

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!

Categories

image
Product Related Updates
image
Certificates/Accreditation
image
Approval/Launch
image
Clinical Trial Update
image
Licensing/Partnering/Collaboration Deal
image
ODD/BTA/FTA Status
image
Merger/Acquisition
image
Warning/Recalls

Lifescience Intellipedia Pvt. Ltd.

C-89, Sector-65 Noida-U.P. 201301 (India)
Toll-Free: 18004190155
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com

USEFUL LINKS

  • Home
  • Privacy Policy
  • Terms & Conditions
  • Terms Of Use
  • Refund Policy
  • Blogs

OUR PRODUCTS

  • ChemProtel - Product Intelligence
  • CompFolio - One Company Profile
  • CompGroupe - Group Company Profile
  • ChemScape - Data Landscape
  • ChemDmart - E-Market Place
  • DataIntel - Data Analytics/Trends
  • DataFeed - Data News/Feed
  • CompShow- Company Showcase

LOCATION

© Copyright Lifescience Intellipedia Pvt. Ltd.. All Rights Reserved

Fill The Form